Two pharmaceutical companies, both headquartered in countries smaller than most American states, have built a competitive position in obesity and diabetes treatment that no third manufacturer is positioned to challenge before the early 2030s. Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide together generated over $80 billion in 2024 revenue, a figure exceeding the entire global market for any therapeutic class outside of immunology and oncology. The competitive dynamics between these two firms—who have each, separately, become the most valuable companies in their respective national stock markets—are now a more consequential determinant of metabolic medicine’s direction than any payer, regulator, or clinical society.
Tirzepatide and semaglutide are not, despite the way they are sometimes treated in clinical conversation, the same drug at different doses. Semaglutide is a single-receptor agonist of the glucagon-like peptide-1 receptor. Tirzepatide is a dual-receptor agonist of GLP-1 and the glucose-dependent insulinotropic polypeptide receptor. The pharmacological difference, while modest in molecular terms, has translated into consistent advantages for tirzepatide in head-to-head trials of weight reduction at maximally tolerated doses. The advantage is meaningful, in the range of three to five percentage points of additional body weight reduction at one year, and it has structured the competitive dynamics in ways that go beyond the headline efficacy numbers.
Novo Nordisk’s strategic response to tirzepatide’s emergence has been bifurcated. The company has continued to invest in the existing semaglutide franchise, including expansion into cardiovascular indications, kidney disease, and adolescent populations. Simultaneously, it has accelerated development of next-generation candidates—CagriSema, a combination of semaglutide and the amylin analog cagrilintide; amycretin, a single-molecule dual GLP-1/amylin agonist; and a number of less-publicized pipeline candidates. The strategic question is whether any of these can recapture the efficacy advantage that tirzepatide currently holds, and the early phase 3 readouts have produced ambiguous answers.
The CagriSema phase 3 results announced in December 2024 disappointed market expectations. The trial showed roughly 22 percent body weight reduction at 68 weeks—below the 25 percent that analysts had projected and below the 22.5 percent average that tirzepatide had produced in its 72-week SURMOUNT-1 trial. Novo’s stock price fell 17 percent on the announcement. The market reaction was, by some metrics, an overreaction—a 22 percent weight reduction is clinically transformative and roughly equivalent to the best published tirzepatide data. But the strategic implication, that Novo’s most advanced post-semaglutide candidate had not closed the gap with tirzepatide, was substantive.
Lilly’s strategic posture has been considerably more aggressive. The company is advancing retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, through phase 3 development with reported phase 2 data showing weight reductions exceeding 24 percent at 48 weeks—a result that, if it holds in larger trials, would represent another step change in efficacy. Lilly has also launched orforglipron, an oral non-peptide GLP-1 agonist that addresses one of the principal limitations of the current injectable franchise. If retatrutide and orforglipron deliver on their phase 2 readouts, Lilly will have positioned itself with three differentiated products covering the high-end injectable, the next-generation injectable, and the oral category—an unusually complete competitive position.
What complicates the simple Lilly-versus-Novo framing is the increasing competitive position of several Chinese pharmaceutical companies advancing GLP-1 candidates through their own clinical programs. Innovent Biologics, Hengrui Medicine, and several others have advanced GLP-1 and dual-agonist candidates through Chinese phase 3 trials with results that are, in some cases, comparable to the Western incumbents. Whether these candidates can secure FDA approval in the United States, and whether they would be priced aggressively enough to disrupt the Lilly-Novo dynamic, depends on a combination of regulatory pathway questions, manufacturing scale, and commercial willingness to confront the entrenched incumbents.
The pricing strategies of the two incumbents have been more cooperative than the public conversation about pharmaceutical pricing usually permits. Both companies have maintained list prices in the same general range. Both have offered manufacturer copay assistance programs that, while structured differently, produce similar net costs to insured patients. Neither has aggressively undercut the other on net price to capture share—the manufacturing capacity constraints make share-grabbing through price unprofitable when demand exceeds supply at current prices. The economic logic of cooperative pricing in a capacity-constrained duopoly is well-understood and not, in any narrow legal sense, anticompetitive. It is, however, a different market dynamic from the one that pharmaceutical price competition is theoretically supposed to produce, and the implications for patient access at lower price points have been substantial.
The IRA’s inclusion of Ozempic in the second round of Medicare drug price negotiation will introduce a new variable into the pricing dynamic. Wegovy and Zepbound, marketed for obesity rather than diabetes, are not currently subject to the same negotiation pathway, but the boundaries between the indications are increasingly fluid as cardiovascular and renal indications blur the line between weight management and chronic disease treatment. CBO analysis of GLP-1 spending has projected that Medicare alone could spend over $30 billion annually on the class within a decade. How the negotiation regime applies to drugs whose indications evolve mid-life-cycle is one of the more interesting open questions for the IRA architecture.
There is a quieter dimension to the Lilly-Novo dynamic that has received less analytic attention than it deserves. Both companies have been investing heavily in evidence generation around the broader cardiometabolic effects of incretin therapy. The cardiovascular outcomes data from SELECT for semaglutide, the kidney disease data from FLOW, and the various tirzepatide outcomes trials have produced a coherent narrative that incretin-based therapy is not just a metabolic intervention but a treatment for the upstream causes of multiple comorbid conditions. This evidence base is being constructed in parallel with the commercial expansion of the products, and the regulatory expansions, indication labels, and clinical guideline updates that follow it will shape the long-term commercial value of the franchise far more than any single trial readout.
The commercial geography of the dynamic is also worth attention. Novo Nordisk’s home market is Denmark, and the company has historically been more international in its commercial focus than Lilly. Lilly’s home market is the United States, and tirzepatide has been launched first and most aggressively in the US market. The result has been a bifurcated competitive landscape: tirzepatide has higher market share in the US, semaglutide has higher share in much of Europe and emerging markets. Whether this geographic pattern persists or converges as both companies expand globally is one of the open strategic questions. Several emerging market launches in 2025 and 2026 will provide initial data points. STAT reporting on the international rollout has noted that pricing in middle-income markets has been substantially below US prices, with implications for parallel trade and reference pricing comparisons that the manufacturers are managing carefully.
What the two-player nature of this market produces, both for patients and for the broader pharmaceutical industry, is a particular kind of equilibrium. The companies have substantial pricing power and use it. They have continued to invest aggressively in next-generation candidates because each fears the other’s pipeline. They have pursued indication expansions that broaden the population eligible for therapy in ways that no single company would have undertaken without the competitive pressure of the other. They have built manufacturing capacity that, in retrospect, will probably look insufficient. And they have, between them, produced what is now the largest therapeutic class in pharmaceutical history. Whether the duopoly is broken in the next decade by Chinese entrants, by next-generation oral therapies that change the manufacturing equation, by patent expirations that permit aggressive generic competition, or by some combination of these forces, will determine whether the GLP-1 era ends in a competitive market or remains, for the duration of the underlying patents, a two-player game whose terms only the two players themselves are positioned to set.
